Inovio’s Zika Vaccine Selected As 2016 Technology Breakthrough
September 12 2016 - 8:00AM
Inovio Pharmaceuticals, Inc. (NASDAQ:INO) today announced that its
Zika vaccine in development has been named a 2016 Technology
Breakthrough by the editors of Popular Mechanics magazine, the
leading technology voice in the U.S. with millions of readers.
Inovio has advanced its DNA-based Zika vaccine
into two trials in the U.S., Canada and Puerto Rico. Inovio expects
to have results before the end of this year for its U.S. study.
In addition, the CDC estimates Zika will infect more than 25%
of the Puerto Rican population by year end, providing the potential
for Inovio’s Zika vaccine and this study’s placebo control design
to provide exploratory signals of vaccine efficacy. The company
expects to meet with regulators next year to determine the most
efficient path forward to develop its Zika vaccine and help
mitigate this widespread Zika outbreak that has now expanded into
the continental United States.
In selecting Inovio’s Zika vaccine as a 2016
breakthrough technology the magazine cited: “Inovio
Pharmaceuticals, the drug company behind what looks to become the
fastest vaccine ever to come to market, may be able to halt such a
(Zika) spread before it gets out of control. The company shocked
the medical world in June by announcing that its Zika vaccine had
already received FDA approval for human clinical trials, just nine
months after the race to prevent Zika began. If all goes well, its
shot will be available to the public as soon as early 2018.”
Dr. J. Joseph Kim, Inovio’s President & CEO,
said, “This award recognizes the Inovio scientists and engineers
who have advanced Inovio’s Zika vaccine into two human
studies. Inovio was the first to manufacture a Zika vaccine,
the first to begin human trials and we expect to have the first
human trials data late this year.”
Inovio is developing its Zika vaccine, GLS-5700,
with GeneOne Life Science, Inc. (KSE: 011000) and academic
collaborators from the US and Canada who are also working to
advance Inovio’s Ebola and MERS vaccines through clinical
development.
There are no approved vaccines or therapies for Zika virus
infection. While multiple companies and academic groups have
announced development plans for Zika virus vaccines, only Inovio
and a US government research center have started human clinical
studies.
About Inovio Pharmaceuticals,
Inc.
Inovio is taking immunotherapy to the next level
in the fight against cancer and infectious diseases. We are the
only immunotherapy company that has reported generating T cells in
vivo in high quantity that are fully functional and whose killing
capacity correlates with relevant clinical outcomes with a
favorable safety profile. With an expanding portfolio of immune
therapies, the company is advancing a growing preclinical and
clinical stage product pipeline. Partners and collaborators include
MedImmune, The Wistar Institute, University of Pennsylvania, DARPA,
GeneOne Life Science, Plumbline Life Sciences, Drexel University,
NIH, HIV Vaccines Trial Network, National Cancer Institute, U.S.
Military HIV Research Program, and Laval University. For more
information, visit www.inovio.com.
This press release contains certain
forward-looking statements relating to our business, including our
plans to develop electroporation-based drug and gene delivery
technologies and DNA vaccines, our expectations regarding our
research and development programs and our capital resources. Actual
events or results may differ from the expectations set forth herein
as a result of a number of factors, including uncertainties
inherent in pre-clinical studies, clinical trials and product
development programs, including the Zika vaccine GLS-5700, the
availability of funding to support continuing research and studies
in an effort to prove safety and efficacy of electroporation
technology as a delivery mechanism or develop viable DNA vaccines,
the adequacy of our capital resources, the availability or
potential availability of alternative therapies or treatments for
the conditions targeted by the company or its collaborators,
including alternatives that may be more efficacious or cost
effective than any therapy or treatment that the company and its
collaborators hope to develop, issues involving product liability,
issues involving patents and whether they or licenses to them will
provide the company with meaningful protection from others using
the covered technologies, whether such proprietary rights are
enforceable or defensible or infringe or allegedly infringe on
rights of others or can withstand claims of invalidity and whether
the company can finance or devote other significant resources that
may be necessary to prosecute, protect or defend them, the level of
corporate expenditures, assessments of the company's technology by
potential corporate or other partners or collaborators, capital
market conditions, the impact of government healthcare proposals
and other factors set forth in our Annual Report on Form 10-K for
the year ended December 31, 2015, our Form 10-Q for the quarter
ended June 30, 2016, and other regulatory filings from
time to time. There can be no assurance that any product in
Inovio's pipeline will be successfully developed or manufactured,
that final results of clinical studies will be supportive of
regulatory approvals required to market licensed products, or that
any of the forward-looking information provided herein will be
proven accurate.
CONTACTS:
Investors: Bernie Hertel, Inovio Pharmaceuticals, 858-410-3101, bhertel@inovio.com
Media: Jeff Richardson, Inovio Pharmaceuticals, 267-440-4211, jrichardson@inovio.com
Inovio Pharmaceuticals (NASDAQ:INO)
Historical Stock Chart
From Mar 2024 to Apr 2024
Inovio Pharmaceuticals (NASDAQ:INO)
Historical Stock Chart
From Apr 2023 to Apr 2024